Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ensysce Biosciences Inc (NQ: ENSC ) 0.4046 UNCHANGED Streaming Delayed Price Updated: 3:57 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 0.4046 Bid (Size) 0.3815 (10) Ask (Size) 0.4041 (1) Prev. Close 0.4046 Today's Range 0.4046 - 0.4046 52wk Range 0.3711 - 2.210 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset July 09, 2024 Via ACCESSWIRE Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting June 27, 2024 Via ACCESSWIRE Performance YTD -63.55% -63.55% 1 Month -22.93% -22.93% 3 Month -25.21% -25.21% 6 Month -64.51% -64.51% 1 Year -81.09% -81.09% More News Read More Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate June 25, 2024 Via ACCESSWIRE ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024 June 24, 2024 Via InvestorPlace Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket June 21, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session June 20, 2024 Via Benzinga Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program June 06, 2024 Via ACCESSWIRE Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting June 03, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Tuesday's After-Market Session June 18, 2024 Via Benzinga Ensysce Biosciences Regains Compliance with Nasdaq May 28, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Thursday's Pre-Market Session May 23, 2024 Via Benzinga Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform May 20, 2024 Via ACCESSWIRE Ensysce Biosciences Reports First Quarter 2024 Financial Results May 13, 2024 Via ACCESSWIRE Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine April 25, 2024 Via ACCESSWIRE Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published April 19, 2024 Via ACCESSWIRE Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results March 15, 2024 Via ACCESSWIRE Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference April 09, 2024 Via ACCESSWIRE FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today March 18, 2024 Via InvestorPlace ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023 March 18, 2024 Via InvestorPlace Ensysce Biosciences Receives Positive Nasdaq Listing Determination February 27, 2024 Via ACCESSWIRE Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection February 21, 2024 Via ACCESSWIRE Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript February 15, 2024 Via ACCESSWIRE Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference February 06, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 13, 2024 Via Benzinga Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds February 13, 2024 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
